混合PET/MRI在子宫内膜癌分期中的诊断与预测价值:一项前瞻性队列研究
前瞻性单中心研究纳入35例活检证实的子宫内膜癌患者,术前接受18F-FDG PET/MRI分期,以组织学为参考标准。PET/MRI检测淋巴结受累灵敏度0.8571、特异度0.9286、准确率0.9143;深肌层浸润准确率77.1%。MRI参数可预测风险分组,MRI与PET参数可预测淋巴血管间隙浸润。
要点
- PET/MRI检测淋巴结转移灵敏度0.8571、特异度0.9286、准确率0.9143,阴性预测值0.9630。
- PET/MRI评估深肌层浸润准确率77.1%,阳性预测值0.8889,阴性预测值0.647。
- MRI总肿瘤体积、体积指数和肿瘤体积比可预测高危及低危分组。
核心结论
- 18F-FDG PET/MRI在子宫内膜癌术前分期中具有良好准确率;PET与MRI参数在术前预测淋巴血管间隙浸润方面具有协同作用,MRI参数还可预测子宫内膜癌风险分组。
研究设计与样本
- 前瞻性单中心研究纳入35例活检证实的子宫内膜癌患者,于2018年12月至2021年3月术前行18F-FDG PET/MRI分期,以组织学检查为参考标准。
- 计算原发肿瘤的PET参数(SUVmax、以SUVmax 40%为阈值的SUVmean即SUVmean40、代谢肿瘤体积、总病灶糖酵解)和MRI参数(体积指数、总肿瘤体积、肿瘤体积比、平均表观扩散系数、最小表观扩散系数)。
- 采用受试者工作特征分析评估PET和MRI参数对子宫内膜癌特征的预测价值。
主要发现
- 患者中位年龄66.57岁(标准差10.21岁),18F-FDG PET/MRI在所有患者中均识别出原发肿瘤。
- 35例中22例为高危子宫内膜癌、13例为低危;13/35例存在淋巴血管间隙浸润,22/35例组织学检查示深肌层浸润,13/35例p53高表达。
- PET/MRI检测淋巴结受累灵敏度0.8571、特异度0.9286、准确率0.9143,阴性预测值0.9630、阳性预测值0.7500。
- PET/MRI评估深肌层浸润正确分期27例(77.1%),灵敏度0.7273、特异度0.8462、准确率0.7714,阳性预测值0.8889、阴性预测值0.647。
- MRI总肿瘤体积、体积指数和肿瘤体积比预测高危及低危分组有统计学意义(P分别为0.0059、0.0235、0.0181);MRI体积、体积指数、肿瘤体积比及PET代谢肿瘤体积和总病灶糖酵解可预测淋巴血管间隙浸润(P分别为0.0023、0.0068、0.0068、0.0027、0.01394);影像无法预测分级、深肌层浸润及p53高表达。
关键数值与推荐
- 淋巴结受累:灵敏度0.8571、特异度0.9286、准确率0.9143、阴性预测值0.9630、阳性预测值0.7500。
- 深肌层浸润:正确分期27/35例(77.1%)、灵敏度0.7273、特异度0.8462、准确率0.7714、阳性预测值0.8889、阴性预测值0.647。
- 风险分组预测:MRI总肿瘤体积P=0.0059、体积指数P=0.0235、肿瘤体积比P=0.0181。
- 淋巴血管间隙浸润预测:MRI体积P=0.0023、体积指数P=0.0068、肿瘤体积比P=0.0068、PET代谢肿瘤体积P=0.0027、总病灶糖酵解P=0.01394。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: The assessment of deep myometrial invasion (MI) and lymph node involvement is of utmost importance in the preoperative staging of endometrial cancer (EC). Imaging parameters derived respectively from MRI and PET have shown good predictive value. The main aim of the present study is to assess the diagnostic performance of hybrid 18F-FDG PET/MRI in EC staging, with particular focus on MI and lymphnodal involvement detection. PATIENTS AND METHODS: Prospective monocentric study including 35 patients with biopsy-proven EC undergoing preoperative 18F-FDG PET/MRI (December 2018-March 2021) for staging purpose. Histological examination was the reference standard. PET (SUVmax, SUVmean with a threshold of 40% of SUVmax-SUVmean40, metabolic tumor volume, total lesion glycolysis) and MRI (volume index [VI], total tumor volume, tumor volume ratio [TVR], mean apparent diffusion coefficient, minimum apparent diffusion coefficient) parameters were calculated on the primary tumor, and their role in predicting EC risk group, the presence of lymphovascular space invasion (LVSI), and MI was assessed. Receiver operating characteristics analysis was used to assess the predictive value of PET and MRI parameters on EC characteristics. RESULTS: Patients' median age was 66.57 years (SD, 10.21 years). 18F-FDG PET/MRI identified the primary tumor in all patients. Twenty-two of 35 patients had high-risk EC and 13/35 low-risk disease; 13/35 presented LVSI, 22/35 had deep MI at histological examination, and 13/35 had p53 hyperexpression.PET/MRI was able to detect lymphnodal involvement with high accuracy and high specificity (sensitivity of 0.8571, specificity of 0.9286, accuracy of 0.9143), also showing a high negative predictive value (NPV) for lymphnodal involvement (NPV of 0.9630, positive predictive value [PPV] of 0.7500).The assessment of deep MI using PET/MRI correctly staged 27 patients (77.1%; sensitivity of 0.7273, specificity of 0.8462, accuracy of 0.7714), with also a good PPV (PPV of 0.8889, NPV of 0.647).MRI-derived total tumor volume, VI, and TVR were significant in predicting EC groups (high-risk vs low-risk patients) (P = 0.0059, 0.0235, 0.0181, respectively). MRI-derived volume, VI, TVR, and PET-derived metabolic tumor volume and total lesion glycolysis were able to predict LVSI (P = 0.0023, 0.0068, 0.0068, 0.0027, 0.01394, respectively). Imaging was not able to predict grading, presence of deep MI, nor hyperexpression of p53. CONCLUSIONS: 18F-FDG PET/MRI has good accuracy in preoperative staging of EC; PET and MRI parameters have synergic role in preoperatively predicting LVSI, with MRI parameters being also predictive for EC risk group.
引用
- Ironi G, Mapelli P, Bergamini A, et al. Hybrid PET/MRI in Staging Endometrial Cancer: Diagnostic and Predictive Value in a Prospective Cohort. Clin Nucl Med. 2022. PMID: 35067539. doi:10.1097/RLU.0000000000004064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。